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Plasma aldosterone concentration in the patient with diabetes
mellitus.
Background. Vascular injury at the microvascular and
macrovascular levels plays a crucial role in the patient with di-
abetes mellitus. Evidence for renin-system activation in many
patients with type 1 diabetes mellitus has raised the possibility
that aldosterone—widely recognized as a contributor to vascu-
lar injury—could play a role.
Methods. We examined the state of the renin-angiotensin-
aldosterone system (RAAS) in 58 subjects with type 1 dia-
betes mellitus and 64 age-matched normal control subjects. All
studies were performed on a fixed sodium (200 mmol/day) and
potassium (100 mmol/day intake), and samples were drawn at
8:00 a.m. to avoid the influence of circadian rhythms.
Results. The patient with diabetes mellitus showed an in-
crease in plasma renin activity (PRA) (P < 0.01), plasma an-
giotensin II concentration (P < 0.01), and plasma aldosterone
concentration (P < 0.001). A striking influence of the an-
giotensin receptor blocker, candesartan, on plasma aldosterone
concentration in the patients with diabetes mellitus suggested
strongly that renin-system activation is responsible for the ele-
vated plasma aldosterone concentration.
Conclusion. Pharmacologic interruption of the effects of al-
dosterone at the tissue level could be especially useful in pa-
tients with diabetes mellitus. The dose of agents that block the
renin-angiotensin system (RAS) should be adjusted to maxi-
mize the fall in plasma aldosterone concentration.
Vascular injury at the macrovascular and microvascu-
lar level is a pivotal complication of diabetes mellitus.
A remarkable range of suggestions has been made on
the factors contributing to vascular injury [1–5]. Among
these possibilities, the contribution of renin-angiotensin-
system (RAS) activation is supported strongly by the
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clear efficacy of angiotensin-converting-enzyme (ACE)
inhibitors and angiotensin receptor blocking agents in
modifying vascular injury in such patients [6–11]. More-
over, a number of observations suggest that the RAS is
activated in many such patients [12].
There has been growing interest in the possibility that
aldosterone contributes to tissue injury through mech-
anisms beyond its influence on blood pressure [1–3].
Recent reviews have suggested that plasma aldosterone
concentration is normal in patients with diabetes mellitus
[1, 12], but the literature referred to is ambiguous for a
number of reasons. Plasma aldosterone concentration is
influenced not only by sodium and potassium intake, and
posture, but also by the time of day at which the sample
is collected: There are powerful circadian rhythms in the
control of aldosterone release. In few studies has sodium
or potassium intake been controlled and careful atten-
tion paid to the time of day at which the blood sample
was drawn for measurement of plasma aldosterone con-
centration. In this study we dealt prospectively with these
issues. A number of observations suggest that the renin
system is often activated in patients with type 1 diabetes
mellitus and in relevant animal models, through mech-
anisms that remain somewhat obscure [12]. This study
was designed to test the hypothesis that activation of the
renin system led to an increase in plasma aldosterone con-
centration, identifying yet another pathway that could
contribute to tissue injury. Evidence that an increased
aldosterone level contributes to tissue injury in diabetes,
and that this is reversed by the addition of an aldosterone
antagonist to ACE inhibition therapy is immediately
relevant [13].
METHODS
Subjects and protocols
We studied 58 men and women with type 1 diabetes
mellitus ranging in age from 18 to 62 years (28.2 ±
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1.5 years) and 64 normal subjects who ranged in age
from 17 to 50 years (31.3 ± 4.0 years). The duration
of diabetes ranged from 2 to 40 years (mean 15.4 ±
1.4 years). Type 1 diabetes mellitus was diagnosed ac-
cording to accepted guidelines [14]. All were free of overt
nephropathy, but were otherwise unselected, and repre-
sent sequential admissions to the study. The subjects were
studied during admission to a metabolic ward, the Gen-
eral Clinical Research Center (GCRC) at the Brigham
and Women’s Hospital, where balance was achieved on a
controlled diet. The protocol was approved by the Human
Subjects Committee at Brigham and Women’s Hospital,
and written-informed consent was obtained from each
subject.
All of the patients and normal subjects were Caucasian.
Of the diabetic patients, 29 had no other past medical his-
tory and were taking no medications aside from insulin.
Of the remaining 29, each had one or more complica-
tions linked to diabetes. Specifically, there were nine cases
of mild-to-moderate retinopathy, eight of proteinuria,
microalbuminuric levels in seven, and near-nephrotic
range in eight, five with neuropathy, four with hyper-
tension, and 14 with hyperlipidemia. The hypertensive
patients were being treated with an ACE inhibitor, an an-
giotensin receptor blocker, or a calcium channel blocking
agent. The drugs were discontinued 10 to 14 days before
admission for study.
All participants were placed on a high-salt isocaloric
diet starting 2 days prior to admission and continuing
throughout the hospitalization, with a daily sodium in-
take of 200 mmol. Daily dietary potassium (100 mmol)
and fluid intake (2500 mL) were constant. Twenty-four–
hour urine samples were collected daily and analyzed for
sodium, potassium, creatinine, and protein.
On the morning of the study day, an intravenous
catheter was placed in both arms of each subject. In the
subjects with diabetes, this was for continuous infusion of
insulin that was started at 0.015 units/kg/hour at 6:00 a.m.
Blood glucose was measured every 30 minutes (Preci-
sion PCX; Abbott Laboratories, Chicago, IL, USA). The
insulin infusion was adjusted to maintain blood glucose
at levels of about 100 mg/dL. The subjects were supine
and had been fasting for at least 8 hours. Hormonal mea-
surements were made on blood samples obtained within
minutes of 8:00 a.m. and at intervals after candesartan
(25 mg orally) administration in a subset while the sub-
jects were lying supine.
Blood pressure was recorded during each study by an
automatic recording device (Dinamap; Critikon, Tampa,
FL, USA) at 5-minute intervals.
Laboratory procedures
Blood samples were collected on ice, spun immediately,
and the plasma was frozen, and stored at –70◦C until as-
Table 1. Demographics
Type 1
diabetes
mellitus Normal
Number 58 64
Age years 28.3 ± 1.5 31.3 ± 4.0
Duration of diabetes mellitus years 15.4 ± 1.4
Gender male/female 32/26 39/25
Body mass index kg/m2 25.4 ± 0.4 24.9 ± 0.5
Systolic blood pressure mm Hg 123 ± 3 116 ± 3
Diastolic blood pressure mm Hg 76 ± 6 65 ± 2
Hemoglobin A1C % 7.9 ± 0.2 —
Fasting blood sugar mg/dL 170 ± 1.0 79 ± 14
Serum creatinine mg/dL 1.0 ± 0.01 0.9 ± 0.03
Serum sodium mEq/L 140 ± 0.4 141 ± 0.3
Serum potassium mEq/L 4.3 ± 0.09 4.3 ± 0.05
24-hour urine sodium mEq 251 ± 14 254 ± 17
24-hour urine potassium mEq 57 ± 3 49 ± 6
say. Urinary sodium and serum potassium levels were
measured using the ion selective electrode. Plasma renin
activity (PRA) and aldosterone were determined by ra-
dioimmunoassay [15, 16]. Hemoglobin A1C (HbA1C) was
measured by high-performance liquid chromatography
(HPLC). The normal range is 4.4% to 6.3%.
Analyses
Group means were calculated with the standard error
of the mean (SEM) as the index of dispersion. Pearson’s
correlation was used to test the association of PRA to
plasma aldosterone concentration. Paired t test was used
to assess the adrenal response to candesartan. Fisher ex-
act test, t test, and the Wilcoxon rank sum test were used
to compare the normals and patients. Analysis of covari-
ance (ANCOVA) was performed to account for possi-
ble confounding effects of baseline characteristics on re-
sponses to candesartan.
RESULTS
The demographic and relevant clinical information is
summarized in Table 1. The normal subjects and patients
with type 1 diabetes were well matched for age, gen-
der distribution, body mass index (BMI), and 24-hour
urine sodium and potassium excretion. Although hyper-
tension was uncommon, both systolic and diastolic blood
pressures were significantly higher in the patients with
type 1 diabetes (P < .05). Out of the 58 diabetics, there
were five in whom BMI exceeded 30. Systolic blood pres-
sure exceeded 140 mm Hg in four, but diastolic blood
pressure was less than 90 mm Hg in all but two. HbA1C
concentration exceeded 9.0 in nine.
The baseline hormonal status of the normal subjects
and the patients with type 1 diabetes mellitus in blood
samples drawn at 8:00 a.m. is shown in Figure 1. As an-
ticipated, PRA was significantly higher in the patients
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Fig. 1. Renin-angiotensin-aldosterone status
in patients with type 1 diabetes mellitus. Note
the parallel increase in plasma renin activity
(PRA), plasma-angiotensin II concentration
(Ang II), and plasma aldosterone concentra-
tion in patients with type 1 diabetes melli-
tus. Body position, time of day, and intake of
sodium and potassium were standardized.
Table 2. Response of plasma aldosterone to the angiotensin receptor
blocker, candesartan
Normal Diabetic
Baseline 4.9 ± 0.6 6.2 ± 1.5
225 minutes 3.9 ± 0.9 3.1 ± 0.5a
aP < 0.01.
with diabetes (0.58 ± 0.06) than in the normal subjects
(0.38 ± 0.06 ng/angiotensin I/mL/hour; P < 0.001). The
increase in PRA was paralleled by an increase in plasma
angiotenin II concentration, 23.3 ± 1.9 ng/mL in the nor-
mal subjects versus 34.7 ± 3.8 ng/mL in the patients with
diabetes (P < 0.01). Similarly, plasma aldosterone con-
centration was increased in the patients with type 1 dia-
betes mellitus (5.1 ± 0.8 ng/mL) in comparison with the
normal subjects (2.6 ± 0.26 ng/mL; P < 0.01). The 63%
increase in PRA was associated with an 89% increase
in plasma aldosterone concentration, and the correlation
between the two was statistically significant (r = 0.48;
P < 0.001).
As anticipated in the patients with type 1 diabetes,
candesartan led to a sharp, statistically significant fall in
plasma aldosterone concentration from 6.2 ± 1.5 ng/mL
to 3.1 ± 0.5 ng/mL (Table 2). The fall in plasma al-
dosterone concentration in the normal subjects did not
achieve statistical significance.
There was no difference in plasma aldosterone concen-
tration in the type 1 diabetics who were free of complica-
tions and those who had microalbuminuria, retinopathy,
hypertension, or hyperlipidemia.
DISCUSSION
Evidence of RAS activation in patients with type 1 di-
abetes mellitus led to several linked hypotheses tested
in this study. The first hypothesis was that plasma al-
dosterone concentration would be elevated in patients
with type 1 diabetes mellitus. Two additional hypotheses
involved the mechanism responsible for the increase in
plasma aldosterone concentration. Our second hypoth-
esis was that an increase in PRA would parallel the in-
crease in plasma aldosterone concentration. Our third
hypothesis was that blockade of the RAS would lead to a
fall in plasma aldosterone concentration in patients with
diabetes mellitus. The results of this study confirm these
hypotheses. Type 1 diabetes was associated with a highly
significant and correlated increase in PRA and plasma
aldosterone concentration. Plasma aldosterone concen-
tration fell sharply in response to the angiotensin receptor
blocker, providing compelling evidence for activation of
the renin system as a major contributor in accord with
our second hypothesis.
One potential confounder in such studies involves the
powerful circadian rhythms that govern plasma aldos-
terone concentration. Over the several hours of this
study, from 8:00 a.m. to early afternoon, there is nor-
mally a sharp fall in plasma aldosterone concentration
in the absence of any external force leading to a re-
duction [17, 18]. In the absence of a placebo group, not
employed in this study, it is impossible to assess the con-
tribution of that normal circadian rhythm to changes in
plasma aldosterone concentration. In an earlier study in
normal subjects on a low-salt diet we documented that
agents that block the RAS led to a fall in plasma aldos-
terone concentration that exceeded the fall in an internal
placebo-treated group [18]. It is likely that both factors
contributed to the fall of plasma aldosterone concentra-
tion in the diabetics in this study. The failure of plasma
aldosterone concentration to fall significantly in response
to candesartan in the normal subjects probably reflects
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the fact that the study was performed on a high-salt diet,
which induced the anticipated suppression of the RAS,
and thus reduced the contribution of angiotensin II to
aldosterone release.
The rationale for performing this study on a high-salt
diet involves two factors. Virtually every one of our sub-
jects with diabetes mellitus had continued glycosuria. The
resultant osmotic diuresis would lead to loss of sodium
in the urine. As a consequence, the depletion of sodium
would be greater in the patients with diabetes than in the
normal subjects on a low-salt diet. Second, inappropriate
activation of a system is typically most easily documented
when the system is normally suppressed—as with a high-
salt diet.
Two other factors that stimulate aldosterone release,
serum potassium concentration and adrenocorticoid hor-
mone, as reflected in plasma cortisol concentration, were
noncontributory in this study. The potential influence of
glucose movement across cell membranes with a paral-
lel shift of potassium makes potassium homeostasis an
attractive contributor to plasma aldosterone concentra-
tion. Plasma cortisol concentration did not differ between
normal subjects and diabetics. Similarly, serum potassium
concentration could not account for the differences in
plasma aldosterone concentration. More frequent mea-
surements of serum potassium concentration over time
might uncover an influence that was missed in this study,
as serum potassium concentration was measured only at
baseline at 8:00 a.m.
Hyperglycemia is a clear candidate for the activation
of the RAS in many patients with type 1 diabetes in this
study, in confirmation of Miller et al [19, 20]. Activation
of the RAS was associated with an influence on the re-
nal blood supply that rendered the kidney more respon-
sive to the angiotensin receptor blocker, losartan. In our
studies, a similar influence was shown on the renal hemo-
dynamic response to the ACE inhibitor, captopril, and
the angiotensin receptor blocker, candesartan [21]. This
study extends the influence of activation of the renin-
angiotensin-aldosterone system (RAAS) to adrenal al-
dosterone release with additional implications for the
pathogenesis of vascular injury. Unfortunately, neither
ACE inhibition nor angiotensin receptor blockers lead to
a sustained, predictable fall in plasma aldosterone [13].
What of type 2 diabetes mellitus? The state of the RAS
is much more variable in type 2 diabetes, PRA often being
suppressed [12]. At the extreme in patients with type 2 di-
abetes mellitus is a syndrome known as “hyporeninemic
hypoaldosteronism” in which a suppressed renin system
is associated with a striking reduction in aldosterone re-
lease and plasma aldosterone concentration—the oppo-
site of the findings in this study. In an earlier report from
this laboratory, we described an increase in plasma al-
dosterone concentration in patients with type 2 diabetes
compared to normal as large as that described in the study
[22]. We did not draw attention to the finding because
there had been no prior hypothesis. It was that obser-
vation that led to the specific hypothesis underlying this
study. Moreover, in that study [22], we showed that a re-
duction in PRA could be misleading, masking an increase
in the activity of the system at the tissue level, at least
within the kidney. It is not clear whether the adrenal par-
ticipates in the process at the tissue level from these data.
PRA was clearly increased in the patients in this study.
The available data suggests that aldosterone is playing a
role in renal injury [13, 23].
Vascular injury at the level of large conduit arteries
and at the arteriolar level is important in the pathogen-
esis of complications of diabetes mellitus. An array of
plausible mechanisms is under active investigation [1–5].
Identification of new pathogenetic pathways creates an
opportunity for new therapeutic approaches. In view of
growing evidence that aldosterone can contribute to vas-
cular injury the possibility that observations in this study
are relevant to therapy cannot be ignored.
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